Applying complexed prostate-specific antigen to clinical practice.

[1]  H. Klocker,et al.  Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/mL. , 2003, Urology.

[2]  W. Rayford,et al.  Complexed PSA performance for prostate cancer detection in an African-American population. , 2003, Urology.

[3]  T. Stamey,et al.  Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. , 2003, The Journal of urology.

[4]  S. Loening,et al.  A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. , 2003, The Journal of urology.

[5]  William J Catalona,et al.  Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. , 2003, The New England journal of medicine.

[6]  W. Rayford,et al.  Similar age-specific PSA, complexed PSA, and percent cPSA levels among African-American and white men of southern Louisiana. Prostate-specific antigen. , 2003, Urology.

[7]  J. Kolker,et al.  Age-related reference ranges for complexed prostate-specific antigen and complexed/total prostate-specific antigen ratio: results from East Texas Medical Center Cancer Institute screening campaign. , 2002, Urology.

[8]  D. Chan,et al.  Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. , 2002, Urology.

[9]  A. Zlotta,et al.  Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective mu , 2002, Urology.

[10]  A. Partin,et al.  Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening. , 2002, Urology.

[11]  T. Stamey,et al.  Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. , 2002, Urology.

[12]  A. Partin,et al.  Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. , 2002, Urology.

[13]  M. Brawer.  Clinical usefulness of assays for complexed prostate-specific antigen. , 2002, The Urologic clinics of North America.

[14]  A. Partin,et al.  Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. , 2001, Urology.

[15]  D. Johnston,et al.  Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. , 2001, The Journal of urology.

[16]  I. Ross,et al.  A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. , 2001, The Journal of urology.

[17]  D. Chan,et al.  Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. , 2000, The Journal of urology.

[18]  E. Higashihara,et al.  Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. , 2000, Urology.

[19]  D. Chan,et al.  Multicenter Evaluation of the Performance and Clinical Utility in Longitudinal Monitoring of the Bayer Immuno 1™ Complexed PSA Assay , 1999, The International journal of biological markers.

[20]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.